K. Serafin et al. / Bioorg. Med. Chem. 19 (2011) 5000–5005
5005
4.2.11. 3-Oxo-3-(toluene-4-sulfonylamino)-propionic acid ethyl
ester, 2j
Mp 97–98 °C (lit. mp 98 °C).35
References and notes
1. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Nat. Rev. Drug Discov. 2004, 3,
660.
All reagents were purchased from Aldrich. Kieselgel 60, 0.040–
0.063 mm (Merck, Darmstadt, Germany) was used for column
chromatography. TLC experiments were performed on alumina-
backed silica gel 40 F254 plates (Merck, Darmstadt, Germany).
The plates were illuminated under UV (254 nm) and evaluated in
iodine vapour. The melting points were determined on a Boetius
PHMK 05 instrument (VEB Kombinat Nagema, Radebeul, Germany)
and are uncorrected. Elemental analyses were carried out on an
automatic Perkin-Elmer 240 microanalyser (Boston, USA) for C,
H, N and are within 0.4% of theoretical values. The purity of the fi-
nal compounds was checked using TLC. All 1H NMR spectra were
recorded on a Bruker AM-500 (499.95 MHz for 1H), Bruker BioSpin
Corp., Germany. Chemical shifts are reported in ppm (d) against the
internal standard, Si(CH3)4. Easily exchangeable signals were omit-
ted when diffuse.
Melting points were measured in an open capillary on an Opti-
Melt (SRS) melting point apparatus and are uncorrected. 1H NMR
spectra were recorded at 400 MHz in DMSO solutions on a Bruker
UltraShield™ NMR spectrometer. The chemical shifts are as parts
per million (d ppm) from TMS as an internal standard. ESI-MS were
determined using a Varian 500-MS mass spectrometer and signals
were recorded in m/z. Elemental analysis was performed using a
Perkin-Elmer CHNS/O Series II 2400 elemental analyser.
2. Hajduk, P. J.; Greer, J. Nat. Rev. Drug Discov. 2007, 6, 211.
3. Law, R.; Barker, O.; Barker, J. J.; Hesterkamp, T.; Godemann, R.; Andersen, O.;
Fryatt, T.; Courtney, S.; Hallett, D.; Whittaker, M. J. Comput. Aided Mol. Des.
2009, 23, 459.
4. Chen, Y.; Shoichet, B. K. Nat. Chem. Biol. 2009, 5, 358.
5. Bartoli, S.; Fincham, C. I.; Fattori, D. Curr. Opin. Drug Discov. Dev. 2007, 10, 422.
6. Mekouar, K.; Mouscadet, J. F.; Desmaële, D.; Subra, F.; Leh, H.; Savouré, D.;
Auclair, C.; d’Angelo, J. J. Med. Chem. 1998, 41, 2846.
7. Pommier, Y.; Johnson, A. A.; Marchand, C. Nat. Rev. Drug Discov. 2005, 4, 236.
8. Luo, Z. G.; Tan, J. J.; Zeng, C. X.; Hu, L. M. Mini-Rev. Med. Chem. 2010, 10, 1046.
9. Ramkumar, K.; Neamati, N. Core Evid. 2010, 15, 131.
10. Chen, J. H.; Linstead, E.; Swamidass, S. J.; Wang, D.; Baldi, P. Bioinformatics
2007, 23, 2348.
11. Grzybowski, B. A.; Bishop, K. J.; Kowalczyk, B.; Wilmer, C. E. Nat. Chem. 2009, 1,
31.
12. Mouscadet, J. F.; Desmaële, D. Molecules 2010, 15, 3048.
13. Polanski, J.; Zouhiri, F.; Jeanson, L.; Desmaële, D.; d’Angelo, J.; Mouscadet, J. F.;
Gieleciak, R.; Gasteiger, J.; Le Bret, M. J. Med. Chem. 2002, 45, 4647.
14. Maurin, C.; Bailly, F.; Mbemba, G.; Mouscadet, J. F.; Cotelle, P. Bioorg. Med.
Chem. 2006, 14, 2978.
15. Bénard, C.; Zouhiri, F.; Normand-Bayle, M.; Danet, M.; Desmaële, D.; Leh, H.;
Mouscadet, J. F.; Mbemba, G.; Thomas, C. M.; Bonnenfant, S.; Le Bret, M.;
d’Angelo, J. Bioorg. Med. Chem. Lett. 2004, 17, 2473.
16. Polanski, J.; Niedbala, H.; Musiol, R.; Podeszwa, B.; Tabak, D.; Palka, A.; Mencel,
A.; Finster, J.; Mouscadet, J. F.; Le Bret, M. Lett. Drug Des. Discov. 2006, 3, 175.
17. Polanski, J.; Niedbala, H.; Musiol, R.; Podeszwa, B.; Tabak, D.; Palka, A.; Mencel,
A.; Mouscadet, J. F.; Le Bret, M. Lett. Drug Des. Discov. 2007, 4, 99.
19. Ukrainets, I.; Bezugly, P.; Treskach, V.; Taran, S.; Gorokhora, O. Tetrahedron
1994, 50, 10331.
20. Boros, E. E.; Johns, B. A.; Garvey, E. P.; Koble, C. S.; Miller, W. H. Bioorg. Med.
Chem. Lett. 2006, 16, 5668.
4.3. Biological activity measurements
21. Deng, J.; Sanchez, T.; Neamati, N.; Briggs, J. M. J. Med. Chem. 2006, 49, 1684.
22. Tchertanov, L.; Mouscadet, J. F. J. Med. Chem. 2007, 50, 1133.
23. Bak, A.; Magdziarz, T.; Kurczyk, A.; Polanski, J. Drug Dev. Res. 2011, 72, 209.
24. Bak, A.; Magdziarz, T.; Kurczyk, A.; Polanski, J. Comb. Chem. High Throughput
Screen 2011, 14, in press.
25. Hare, S.; Vos, A. M.; Clayton, R. F.; Thuring, J. W.; Cummings, M. D.; Cherepanov,
P. PNAS 2010, 107, 20057.
26. Savarino, A. Retrovirology 2007, 20, 4.
IN was expressed and purified as described previously.36 For
activity assays, 100 pmol of U5B were radiolabelled using T4 poly-
nucleotide kinase and 50 Ci of [32P]ATP (3000 Ci/mmol). The T4 ki-
nase was then heat-inactivated, and unincorporated nucleotides
were removed by filtration through a Sephadex G-25 column
(Amersham Biosciences AB, Uppsala, Sweden). NaCl was added to
a final concentration of 100 mM and the complementary unlabeled
strand U5A was added. The mixture was incubated at 90 °C for
3 min and allowed to anneal by slowly cooling to room tempera-
ture. The 3-processing and strand transfer reactions were per-
formed using 1.5 nM U5A/U5B and 10 nM U5A double-stranded
oligonucleotide substrates, respectively, in a buffer containing
20 mM HEPES, pH 6.8, 7.5 mM MgCl2, and 2 mM DTT in the pres-
ence of various concentrations of IN. The reaction mixture was
incubated for 1 h at 37 °C and stopped by phenol–chloroform
extraction. Chemical structures were dissolved in DMSO and sub-
jected to electrophoresis on an 18% denaturing acrylamide/urea
gel. Gels were dried and the reaction products were visualized
using a STORM PhosphorImager (Amersham Biosciences). IC50
were obtained from a nonlinear regression fitting of the dose–re-
sponse curves using IMAGE QUANT TL software.
27. Loizidou, E. Z.; Zenelipour-Yazdi, C. D.; Christofides, T.; Kostrikis, L. G. Bioorg.
Med. Chem. 2009, 17, 4806.
28. Hazuda, J. D.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.;
Fisher, T. E.; Embrey, M.; Guare, J. P.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.;
Felock, P. J.; Witmer, M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M.
D.; Espeseth, A. S.; Jin, L.; Chen, I. W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong,
B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.; Emini, E.; Summa, V.;
Holloway, M. K.; Young, S. D. PNAS 2004, 101, 11233.
29. Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P. Nature 2010, 464,
232.
30. Molecular Operating Environment (MOE 2008.10), CCG Inc., 1255 University
St., Suite 1600, Montreal, Quebec, Canada H3B 3X3. <http://
31. Mazur, P.; Magdziarz, T.; Bak, A.; Chilmonczyk, Z.; Kasprzycka-Guttman, T.;
Misiewicz, I.; Skupinska, J.; Polanski, J. J. Mol. Model. 2010, 16, 1205.
32. Jeon, M. K.; Kim, K. Tetrahedron Lett. 2002, 43, 3415.
33. Fusco, R.; Rossi, S. Gazzetta Chimica Italiana 1964, 94, 3.
34. Chakraboty, K.; Devakumar, C. J. Agric. Food Chem. 2006, 54, 6800.
35. Morzherin, Y.; Rozin, Y.; Vorobeva, E.; Bakulev, V. Chem. Heterocycl. Compd.
2001, 37, 560.
36. Hazuda, D. J.; Hastings, J. C.; Wolfe, A. L.; Emini, E. A. Nucleic Acids Res. 1994, 22,
1121.
Acknowledgments
This study is supported by grants from the Polish Ministry of
Science N405 178735 and NN519 575638.